Friday, 13 Jul 2018

You are here

Opioid Use in Ankylosing Spondylitis

A prospective study has shown that ankylosing spondylitis (AS) patients often require narcotic analgesics to manage pain unresponsive to antiinflammatory therapies.

AS patients (n=706) were serially assessed (every 6 months) and outcome measures were collected, including disease activity and functional measures (BASDAI, BASFI), along with radiographic outcomes.  Investigators specifically looked at opioid usage.

Factors significantly associated with opioids included longer disease duration, smoking, lack of exercise, higher disease activity (BASDAI) and functional impairment (BASFI), depression, radiographic severity, and cardiovascular disease.

Patients taking opioids were more likely to be using anxiolytic, hypnotic, antidepressant, and muscle relaxant medications.

It appears that subjective measures (depression, BASDAI, BASFI) moreso than objective measures (CRP, ESR), drive opioid use in AS.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Liver Disease Increased in Psoriasis

An observational case-control study has shown that psoriasis is associated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD).

A single center, outpatient dermatology clinic studied 151 patients with psoriasis and 51 control subjects with ultrasonography to diagnose NAFLD.

Best of 2017: Cause of Death in Ankylosing Spondylitis

A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology.

They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009).

The mortality rate of AS remained stable over time.

Ixekizumab Effective in Ankylosing Spondylitis

Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.

NPF Dietary Recommendations for Psoriatic Disease

The National Psoriasis Foundation has released dietary recommendations for adults with psoriasis and psoriatic arthritis, based on a systematic review of the current literature, with the strongest focus on weight reduction for those who are overweight or obese.

Enthesitis in PsA: A New Focus of Treatment?

Patients with psoriatic arthritis (PsA) whose disease manifestations include enthesitis showed significantly greater responses to interleukin (IL)-23 inhibition than to blocking tumor necrosis factor (TNF), suggesting the possibility that treatment decisions in the future might be guided by specific cytokine targeting.